Fluicell (FLUI.ST) Stock Analysis & AI Equity Report
Fluicell (FLUI.ST) overview
Fluicell (FLUI.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Fluicell reported revenue of SEK 1.9m and operating profit of SEK -15.8m; the year-end share price was 14.35 SEK and market capitalisation was SEK 17.0m. Fluicell is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Fluicell's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Fluicell
Fluicell develops microfluidic and single-cell technology for life science research and regenerative medicine. Its products include the BioPen, Biozone 6 and Dynaflow Resolve research tools, the Biopixlar bioprinting platform and the Nexocyte tissue production platform. The company also advances tissue-based therapeutics and screening models for applications such as type 1 diabetes, cardiac toxicity and kidney disease.
Generate the Fluicell report
Fluicell is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Fluicell and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.